Sanofi SA Oncology Strategy and ASCO R&D Investor Event Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Sanofi's Oncology Investor Call. I would now like to turn the call over to Felix Lauscher from Sanofi Investor Relations. Please go ahead, sir.
Good morning, and good afternoon to everyone on the call. Thank you for joining us on the second of 5-part series of interactive webcast events, which will highlight Sanofi's progress in R&D. Event today will focus on our oncology strategy and ASCO updates. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.
As part of the momentum building around our pipeline, following today, we will host our next R&D investor event on June 11, focused on DUPIXENT. We are also excited to confirm that the nirsevimab Phase IIb data has been submitted and accepted by a peer review journal. The nirsevimab investor event will be scheduled around the planned publication date.
Moving to Slide 2. I would like to remind you that information presented
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
